Company Filing History:
Years Active: 2025
Title: The Innovations of Sagar Patni: Pioneering ENPP1 Inhibitors
Introduction
Sagar Patni, an innovative inventor based in Noida, India, has made significant contributions to the field of biomedical research. With a focus on therapeutic compounds, his work centers on addressing conditions linked to the dysfunction of the ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) enzyme. His research is not only groundbreaking but also crucial in advancing medical treatments for various conditions.
Latest Patents
Sagar Patni holds a patent for his invention titled "Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof." This patent discloses novel compounds that are useful in treating conditions associated with the dysfunction of the ENPP1 enzyme. Particularly, the invention presents a compound that exhibits inhibitory activity against ENPP1 and outlines a method for treating conditions linked to the over-expression of the ENPP1 gene. Furthermore, the patent covers various applications, including pharmaceutical compositions and kits that utilize these compounds.
Career Highlights
Mr. Patni is currently associated with 1CBIO, Inc., a company dedicated to driving innovation in the biotech sector. His role within the organization showcases his commitment to developing cutting-edge solutions that can significantly enhance patient care.
Collaborations
Throughout his career, Sagar Patni has collaborated with talented individuals such as Brahmam Pujala and Amantullah Ansari. These partnerships not only bolster his research efforts but also enhance the collective knowledge and expertise within their fields, leading to impactful innovations in healthcare.
Conclusion
Sagar Patni's contributions to the development of ENPP1 inhibitors highlight his role as an invaluable inventor in the realm of biomedical sciences. His patent demonstrates a profound understanding of complex biological systems and stands as a testament to the importance of innovation in addressing critical health challenges. As researchers continue to build upon his work, the potential for new therapeutic strategies remains promising.